Metronomic Chemo – OncWonk – Dr Bier's Oncology Research Reviews

A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer

January 22, 2026

Comment: A central issue in palliative oncology is the historical focus on aggressive salvage therapies that frequently lead to negative impacts on QOL rather than measurable survival gains. Metronomic capecitabine reverses this risk-benefit calculation, delivering a median overall survival of 18 months in responders while reporting no treatment-related deaths or severe toxicities. In a population […]

Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.

December 3, 2025

| No Comments

| Cancer - Breast, Cancer - Colon

Comment: With the caveat that this is an abstract and not the full study, this trial is a crucial validation of the “less is more” principle that come up frequently. The significant improvement in Time to Treatment Failure (TTF) with the Fixed-Dose (7/7) schedule confirms what proponents of metronomic chemotherapy have argued for years: the […]

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

November 2, 2025

| No Comments

| Miscellaneous

Comment: This 2017 article’s real contribution here isn’t the narrative review—which, as is too selective to be high-quality—but the new VICTOR-2 subgroup data. While a 35.7% Clinical Benefit Rate in an elderly (median age 69) metastatic TNBC population is certainly interesting, it’s from a tiny, single-arm cohort of 28 patients. This paper highlights metronomic chemotherapy […]

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

November 2, 2025

| No Comments

| Cancer - Breast

Comment: Metronomic chemotherapy (mCHT) is a concept that’s been around, but it’s often overlooked in favor of high-dose regimens. This 2022 review from J. Clin. Med. brilliantly frames the evidence, separating the clear “lights”—like its low-toxicity profile—from the persistent “shadows” we still face, such as the lack of large randomized trials. For our frail or […]

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

November 2, 2025

| No Comments

| Miscellaneous

Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]

Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials

October 27, 2025

| No Comments

| Cancer - Colon

Comment: This systematic review is, predictably, hampered by significant heterogeneity and an insufficient number of trials, preventing any definitive conclusions. However, an optimistic signal does emerge. The review strongly reinforces the primary value proposition of metronomic chemotherapy: an exceptionally favorable safety profile, with a striking lack of severe hematological toxicity. Furthermore, despite the mixed data, […]

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer

October 26, 2025

| No Comments

| Cancer - Colon

Comment: While this study is flawed by its retrospective design and critical selection bias, we shouldn’t discard the core hypothesis. The authors are right to call the findings preliminary, but the concept of metronomic maintenance therapy remains highly compelling. The fact that such a strong Overall Survival signal (86.8% vs. 68.5%) was detected at all, […]

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

October 26, 2025

| No Comments

| Cancer - Breast

Comment: The MECCA trial, while certainly not practice-changing, provides an important signal for the potential of metronomic chemotherapy. The key takeaway is the therapeutic window. Achieving a 9-month PFS benefit and a positive OS trend with a regimen that produced Grade 3 adverse events in only 15.1% of patients is compelling. This highlights the central […]

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

October 26, 2025

| No Comments

| Cancer - Breast

Comment: This study presents a very practical and appealing option for managing advanced HER2-negative breast cancer in the palliative setting. The key takeaway is the dual advantage of this all-oral metronomic regimen: it demonstrates clinically relevant activity while maintaining an exceptionally low toxicity profile. However, the regimen’s main strength is its safety and convenience. Being […]